Maravai LifeSciences (MRVI) Projected to Post Quarterly Earnings on Monday

Key Points

• Maravai LifeSciences is set to release its Q2 2025 earnings on August 11, with expectations of a loss of ($0.06) per share and revenue of $47.46 million.
• The company reported a loss of ($0.08) per share in the previous quarter, which was below the consensus estimate, despite revenue exceeding expectations at $46.85 million.
• Shares of Maravai LifeSciences are currently priced at $2.22, with a market cap of $565.35 million and a consensus rating of "Hold" among analysts.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results after the market closes on Monday, August 11th. Analysts expect Maravai LifeSciences to post earnings of ($0.06) per share and revenue of $47.46 million for the quarter. Maravai LifeSciences has set its FY 2025 guidance at EPS.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). Maravai LifeSciences had a negative return on equity of 12.91% and a negative net margin of 67.14%. The company had revenue of $46.85 million for the quarter, compared to the consensus estimate of $44.01 million. The firm's revenue was down 26.9% compared to the same quarter last year. On average, analysts expect Maravai LifeSciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Maravai LifeSciences Price Performance

Shares of MRVI traded up $0.17 during trading hours on Friday, reaching $2.20. The stock had a trading volume of 1,581,500 shares, compared to its average volume of 2,459,145. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.17 and a current ratio of 5.96. Maravai LifeSciences has a 12 month low of $1.66 and a 12 month high of $9.95. The stock has a market capitalization of $560.25 million, a PE ratio of -1.93 and a beta of 0.28. The company's 50-day moving average is $2.39 and its two-hundred day moving average is $2.72.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Maravai LifeSciences stock. Jane Street Group LLC lifted its stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 1,463.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 380,403 shares of the company's stock after buying an additional 356,067 shares during the period. Jane Street Group LLC owned about 0.15% of Maravai LifeSciences worth $841,000 at the end of the most recent quarter. Institutional investors and hedge funds own 50.25% of the company's stock.

Wall Street Analyst Weigh In

MRVI has been the topic of several recent research reports. Craig Hallum cut their target price on Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Robert W. Baird cut their price objective on Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $6.64.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.